• Corpus ID: 119431048

Nuclear fusion enhances cancer cell killing efficacy in a protontherapy model

  title={Nuclear fusion enhances cancer cell killing efficacy in a protontherapy model},
  author={G A P Cirrone and Lorenzo Manti and Daniele Margarone and Lorenzo Giuffrida and Antonino Picciotto and Giacomo Cuttone and Georg Korn and V Marchese and G. Milluzzo and Giada Petringa and F. M. Perozziello and F Romano and Valentina Scuderi},
  journal={arXiv: Medical Physics},
Protontherapy is hadrontherapy fastest-growing modality and a pillar in the battle against cancer. Hadrontherapy superiority lies in its inverted depth-dose profile, hence tumour-confined irradiation. Protons, however, lack distinct radiobiological advantages over photons or electrons. Higher LET (Linear Energy Transfer) $^{12}$C ions can overcome cancer radioresistance: DNA lesion complexity increases with LET, resulting in efficient cell killing, i.e. higher Relative Biological Effectiveness… 

Figures and Tables from this paper

New approaches in clinical application of laser-driven ionizing radiation

The planned laser-driven ionizing beams (photon, very high energy electron, proton, carbon ion) at laser facilities have the unique property of ultra-high dose rate (>Gy/s-10), short pulses, and at

An evaluation of the various aspects of the progress in clinical applications of laser driven ionizing radiation

There has been a vast development of laser-driven particle acceleration (LDPA) using high power lasers. This has initiated by the radiation oncology community to use the dose distribution and



Biological modeling of gold nanoparticle enhanced radiotherapy for proton therapy

A biological model is established to investigate the change in survival of irradiated cells due to the radiosensitizing effect of gold nanoparticles, and concludes that if the GNPs cannot be internalized into the cytoplasm, no GNP enhancement will be observed for proton treatment.

Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects

Critical issues that must be addressed include the need for more selective and effective boron delivery agents, the development of methods to provide semiquantitative estimates of tumor borons content before treatment, improvements in clinical implementation of BNCT, and a need for randomized clinical trials with an unequivocal demonstration of therapeutic efficacy.

Charged particle therapy—optimization, challenges and future directions

Charged particles can potentially replace surgery for radical cancer treatments, which might be beneficial as the success of surgical cancer treatments are largely dependent on the expertise and experience of the surgeon and the location of the tumour.

Proton Radiobiology

Data emerging from recent studies suggest that, for several end points of clinical relevance, the biological response is differentially modulated by protons compared to photons, highlighting how a re-discussion of the role of a variable RBE in proton therapy might be well-timed.

Radiotherapy with beams of carbon ions

The central part of this review is devoted to the discussion of the physical, radiobiological and clinical bases of the use of 400 MeV µ−1 carbon ions in the treatment of radio-resistant tumours.

Photon, light ion, and heavy ion cancer radiotherapy: paths from physics and biology to clinical practice.

It is argued that meta-analysis of non-coordinated clinical trials data represents an early stage of investigation that can help inform the design of future RCTs.

Effects of Charged Particles on Human Tumor Cells

This review summarizes the unique biological advantages of charged particle therapy and highlights recent research and areas of particular research needs, such as quantification of relative biological effectiveness (RBE) for various tumor types and radiation qualities.